Working… Menu

Dasotraline Binge Eating Disorder Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02564588
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : September 28, 2017
Information provided by (Responsible Party):

Brief Summary:
Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)

Condition or disease Intervention/treatment Phase
Binge Eating Disorder Drug: Dasotraline Drug: Placebo Phase 2 Phase 3

Detailed Description:
This is a randomized, double blind, parallel group, multicenter, outpatient study evaluating the efficacy and safety of flexibly-dosed dasotraline in adults with BED using dasotraline (4, 6, and 8 mg/day) versus placebo over a 12 week treatment period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 319 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Study Start Date : October 2015
Actual Primary Completion Date : October 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eating Disorders

Arm Intervention/treatment
Experimental: Dasotraline
Dasotraline 4, 6, 8 mg
Drug: Dasotraline
Dasotraline 4, 6, 8mg flexibly dosed once daily

Placebo Comparator: Placebo
Placebo Comparator
Drug: Placebo
Placebo once daily

Primary Outcome Measures :
  1. Change from baseline in number of binge days (defined as days during which at least 1 binge episode occurs) per week to Week 12 [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Change from baseline in number of binge episodes per week to Weeks 1, 2, 3, 4, 6, 8, 10, and 12 [ Time Frame: 12 Weeks ]
  2. Percent of subjects with a 4-week cessation from binge eating (defined as a 100% reduction for at least 28 consecutive days in the number of binge eating episodes prior to the EOT visit) [ Time Frame: 4 weeks ]
  3. Change from baseline in Clinical Global Impression-Severity (CGI S) score at Weeks 2, 4, 6, 8, 10, and 12 [ Time Frame: 12 Weeks ]
  4. Change from baseline in Eating Disorder Examination Questionnaire Brief Version (EDE Q7) global score and 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction) at Weeks 4, 8, and 12 [ Time Frame: 12 Weeks ]
  5. Change from baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y BOCS BE) total score and subscale scores (obsessions and compulsions) at Weeks 2, 4, 6, 8, 10, and 12 [ Time Frame: 12 Weeks ]
  6. Change from baseline in Sheehan disability Scale (SDS) total score and subscale scores (school/work disability, social life disability, and family life disability at Week 12 [ Time Frame: 12 Weeks ]
  7. Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 12 [ Time Frame: 12 Weeks ]
  8. Change from baseline in Hamilton Anxiety Rating Scale (HAM A) score at Week 12 [ Time Frame: 12 Weeks ]
  9. Change from baseline in Medical Outcomes Study 12 Item Short Form (SF 12) two component scores (physical component, mental health component) at Week 12 [ Time Frame: 12 Weeks ]
  10. Proportion of binge-eating responders who have ≥ 75% reduction in the number of binge eating episodes from Baseline at Week 12 [ Time Frame: 12 weeks ]
  11. Proportion of binge-eating responders who have ≥ 50% reduction in the number of binge eating episodes from Baseline at Week 12 [ Time Frame: 12 Weeks ]
  12. The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations [ Time Frame: 12 Weeks ]
  13. Clinical laboratory evaluations (serum chemistry, hematology, and urinalysis) [ Time Frame: 12 Weeks ]
  14. Clinical evaluations (vital signs, orthostatic effects, and 12 lead ECGs) [ Time Frame: 12 Weeks ]
  15. Frequency and severity of suicidal ideation and suicidal behavior as assessed by the Columbia-suicide severity rating scale (C SSRS) [ Time Frame: 12 Weeks ]
  16. Change and percent change from baseline in body weight at Weeks 1, 2, 3, 4, 6, 8, 10, and 12 [ Time Frame: 12 Weeks ]
  17. Change and percent change from baseline in BMI at Weeks 1, 2, 3, 4, 6, 8, 10, and 12 [ Time Frame: 12 Weeks ]
  18. Change from baseline in a fasting lipid panel (triglycerides, total cholesterol, high-density lipoprotein [HDL] cholesterol, and low-density lipoprotein [LDL] cholesterol) at Weeks 6 and 12 [ Time Frame: 12 Weeks ]
  19. Change from baseline in hemoglobin A1c level at Weeks 6 and 12 [ Time Frame: 12 Weeks ]
  20. Change from baseline in fasting glucose level at Weeks 6 and 12 [ Time Frame: 12 Weeks ]
  21. Change in the symptoms of withdrawal from Week 12/end of treatment (EOT) as measured by: - CSSA scores at Weeks 13, 14, and 15 - DESS scores at Weeks 13, 14, and 15 - HAM A scores at Weeks 13, 14, and 15 - MADRS scores at Weeks 13, 14, and 15. [ Time Frame: 3 Weeks ]
    The change in symptoms of withdrawal is a time frame of 3 weeks after treatment ends (weeks 13, 14, 15)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject between 18 and 55 years of age, inclusive, at time of informed consent.
  • Subject meets the following DSM 5 criteria for a diagnosis of BED. An episode of binge eating is characterized by both:
  • Eating an amount of food larger than what most people would eat, in a discrete period of time (eg, 2 hours)
  • Sense of lack of control over eating episode
  • Binge-eating episodes are associated with ≥ 3 of the following:
  • Eating much more rapidly than normal
  • Eating until uncomfortably full
  • Eating large amounts when not feeling hungry
  • Eating alone because of embarrassment
  • Feeling disgusted with oneself, guilty afterward
  • Binge-eating episodes are also associated with marked distress regarding the episode and not associated with recurrent use of compensatory behavior (eg, bulimia nervosa).
  • Diagnosis is confirmed based on the eating-disorders module of the SCID, clinician review of subject diaries, and the EDE Q.
  • Subject has a BED diagnosis including at least 2 binge eating days a week for at least 6 months prior to screening.
  • Subject's BED is of at least moderate severity.
  • Subject has a negative breath alcohol test and a negative urine drug screen (UDS) for any illicit drug.
  • Female subject must have a negative serum pregnancy test at screening; females who are post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test.
  • Female subject of childbearing potential and male subject with female partner of childbearing potential must agree to use an effective and medically acceptable form of birth control throughout the study period. Note: Continued use of an effective and medically acceptable form of birth control is recommended for 30 days after study completion.
  • Subject must be able to comply with study drug administration and adhere to protocol requirements.

Subject can read well enough to understand the informed consent form and other subject materials.

Exclusion Criteria:

  • Subject has body weight index (BMI) of 18 kg/m2or less or greater than 45 kg/m2.
  • Subject has a lifetime history or current symptoms of bulimia nervosa or anorexia nervosa.
  • Subject has started psychotherapy (eg, supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) within 3 months prior to screening. Note: Subjects receiving stable ongoing psychotherapy for longer than 3 months are permitted to enroll.
  • Subject is participating in a formal weight loss program (eg, Weight Watchers®) within 3 months prior to screening.
  • Subject has used a psychostimulant or mood stabilizer within the 3 months prior to screening.
  • Subject has used any medications for the treatment of binge eating, other eating disorders, obesity, or weight gain or any other medication that could result in weight gain or weight loss including over-the-counter and herbal products within the 3 months prior to screening.
  • Subject has a lifetime history of psychotic disorder, bipolar disorder, hypomania, dementia, or ADHD as defined by the DSM 5 criteria.
  • Subject has a history of moderate to severe depression based on investigator's judgment within the 6 months prior to screening or is currently taking or has taken any medication for depression during the 3 months prior to screening.
  • Subject has a history of substance use disorder including alcohol use disorder (excluding nicotine and caffeine) within the 12 months prior to screening, as defined by the DSM 5 criteria.
  • Subject has MADRS score ≥ 18 at screening and Baseline visit.
  • Subject is considered a suicide risk or has any previous history of suicide attempt.
  • Subject answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C SSRS assessment at screening (in the past month). Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation.
  • Subject has type I diabetes mellitus or insulin-dependent diabetes mellitus.
  • Subject with type II diabetes mellitus has hemoglobin A1c ≥ 6.5% at screening, or has initiated treatment with or changed the dose of a glucose-lowering agent within 3 months prior to screening.
  • Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, documented heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
  • Subject has initiated treatment with or changed the dose of a lipid-lowering medication within the 3 months prior to screening.
  • Subject has a history of moderate or severe hypertension that in the investigator's opinion has not been medically stable or has required a change in dosage and/or medication during the 3 months prior to screening.
  • Subject has a history of epilepsy, seizures (except childhood febrile seizures), unexplained syncope or other unexplained blackouts (except single incident), or head trauma with loss of consciousness lasting more than 5 minutes, or a history of clinically significant repeated head-traumas without loss of consciousness.
  • Subject is female and pregnant or nursing.
  • Subject has had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.
  • Subject has a history of positive test for Hepatitis B surface antigen or Hepatitis C antibody with liver function test results at screening above the upper limit of normal (ULN) for the reference laboratory.
  • Subject without a history of positive test for Hepatitis B surface antigen or Hepatitis C antibody has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value ≥ 2 times the ULN at screening.
  • Subject has a blood urea nitrogen (BUN) value ≥ 1.5 times the ULN for the reference range, fasting blood glucose ≥ 126 mg/dL (7.0 mmol/L), or hemoglobin A1c ≥ 6.5% at screening.
  • Subject is known to have tested positive for human immunodeficiency virus (HIV).
  • Subject has a clinically significant abnormality on screening evaluation including physical examination, vital signs, ECG, or laboratory tests that the investigator considers to be inappropriate to allow participation in the study.
  • The subject's screening ECG shows a corrected QT interval using Fridericia's formula (QTcF) of ≥ 450 msec for male subjects or ≥ 470 msec for female subjects. Eligibility will be based on the core laboratory ECG interpretation report.
  • Subject has any life-time history of abuse or diversion of stimulants.
  • Subject has a history of allergic reaction or has a known or suspected sensitivity to any substance that is contained in the study drug formulation.
  • Subject has enrolled in any Phase 2 or 3 trial of psychostimulants including lisdexamfetamine dimesylate (Vyvanse®) for binge-eating disorder.
  • Subject is currently participating or has participated in any clinical trial within the last 90 days or has participated in more than 2 clinical trials within the past year. This includes studies using marketed compounds or devices.
  • Subject has previously been enrolled in a clinical trial of dasotraline (SEP 225289).
  • Subject is an investigational site staff member or the relative of an investigational site staff member.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02564588

  Hide Study Locations
Layout table for location information
United States, California
Southern California Research
Beverly Hills, California, United States, 90210
Southwestern Research, Inc.
Beverly Hills, California, United States, 90210
Pharmacology Research Institute
Encino, California, United States, 91316
Collaborative NeuroScience Network Inc.
Garden Grove, California, United States, 92845
Pharmacology Research Institute
Newport Beach, California, United States, 92660
PCSD- Feighner Research
San Diego, California, United States, 92108
Research Across America
Santa Ana, California, United States, 92705
United States, Colorado
Lytle and Weiss, PLLC
Denver, Colorado, United States, 80209
United States, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States, 32256
Segal Institute for Clinical Research
North Miami, Florida, United States, 33161
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States, 32801
Miami Research Associates
South Miami, Florida, United States, 33143
United States, Georgia
Institute of Advanced Medical Research
Alpharetta, Georgia, United States, 30005
Neurotrials Research, INC.
Atlanta, Georgia, United States, 30342
United States, Illinois
Capstone Clinical Research
Libertyville, Illinois, United States, 60048
United States, Indiana
Goldpoint Clinical Research, Inc.
Indianapolis, Indiana, United States, 46260
United States, Kansas
Cypress Medical Research Center, LLC
Wichita, Kansas, United States, 67226
United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Adams Clinical Trials, LLC
Watertown, Massachusetts, United States, 02472
United States, Missouri
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri, United States, 63304
United States, New Jersey
Princeton Medical Institute, LCC
Princeton, New Jersey, United States, 08540
United States, New York
Bioscience Research, LLC
Mount Kisco, New York, United States, 10549
United States, North Carolina
Wake Research Associates
Raleigh, North Carolina, United States, 27612
United States, Ohio
Radiant Research, Inc.
Akron, Ohio, United States, 44311
Patient Priority Clinical Sites
Cincinnati, Ohio, United States, 45215
Midwest Clinical Research Center
Dayton, Ohio, United States, 45417
Lindner Center Of Hope
Mason, Ohio, United States, 45040
North Star Medical Research, LLC
Middleburg Heights, Ohio, United States, 44130
United States, Oklahoma
IPS Research Company
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
Sunstone Medical Research, LLC
Medford, Oregon, United States, 97504
Oregon Center for Clinical Investigatons, INC.
Portland, Oregon, United States, 97214
Oregon Center for Clinical Investigatons, INC.
Salem, Oregon, United States, 97301
United States, Pennsylvania
Lehigh Center For Clinical Research
Allentown, Pennsylvania, United States, 18104
United States, South Carolina
Radiant Research, Inc.
Anderson, South Carolina, United States, 29621
Radiant Research, Inc.
Greer, South Carolina, United States, 29650
United States, Texas
Furturesearch Trials of Dallas
Dallas, Texas, United States, 75231
Texas Center for Drug Development, Inc.
Houston, Texas, United States, 77081
Psychiatric Medical Associates
Plano, Texas, United States, 75093
United States, Utah
Radiant Research, Inc.
Murray, Utah, United States, 84123
Advanced Research Institute
Ogden, Utah, United States, 84405
United States, Vermont
Neuropsychiatric Associates
Woodstock, Vermont, United States, 05091
United States, Virginia
NeuroScience, Inc.
Herndon, Virginia, United States, 20170
United States, Washington
Summit Research Network (Seattle) LLC
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Layout table for investigator information
Study Director: Dasotraline Medical Director, MD Sunovioin

Layout table for additonal information
Responsible Party: Sunovion Identifier: NCT02564588     History of Changes
Other Study ID Numbers: SEP360-221
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: September 28, 2017
Last Verified: September 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Feeding and Eating Disorders
Binge-Eating Disorder
Pathologic Processes
Mental Disorders
Signs and Symptoms, Digestive
Signs and Symptoms